Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)
Public ClinicalTrials.gov record NCT05898399. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of the DNA Polymerase Theta Inhibitor ART6043 Administered Orally as Monotherapy and in Combination to Patients With Advanced or Metastatic Solid Tumors
Study identification
- NCT ID
- NCT05898399
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Artios Pharma Ltd
- Industry
- Enrollment
- 181 participants
Conditions and interventions
Conditions
Interventions
- ART6043 Drug
- Olaparib Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 29, 2023
- Primary completion
- Jun 29, 2028
- Completion
- Sep 29, 2028
- Last update posted
- Apr 30, 2026
2023 – 2028
United States locations
- U.S. sites
- 7
- U.S. states
- 6
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| South Texas Accelerated Research Therapeutics (START) - Midwest | Grand Rapids | Michigan | 49546 | Active, not recruiting |
| Memorial Sloan-Kettering Cancer Center (MSKCC) | New York | New York | 10065-6800 | Active, not recruiting |
| Stephenson Cancer Center - Oncology | Oklahoma City | Oklahoma | 73104 | Active, not recruiting |
| Jefferson University Hospitals - Kimmel Cancer Center | Philadelphia | Pennsylvania | 17107 | Active, not recruiting |
| SCRI oncology partners | Nashville | Tennessee | 37203 | Completed |
| Mary Crowley Cancer Center - Clinic | Dallas | Texas | 75251 | Completed |
| The University of Texas - MD Anderson Cancer Center | Houston | Texas | 77030 | Active, not recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 5 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05898399, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 30, 2026 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05898399 live on ClinicalTrials.gov.